Keeping at-risk cells from developing cancer

User rating: 4.8 / 5 after 12 vote(s)

Researchers at Johns Hopkins have discovered that cancers arising from epigenetic changes - in this case the inappropriate activation of a normally silent gene - develop by becoming addicted to certain growth factors. Reporting online in next week’s Early Edition of the Proceedings of the National Academies of Sciences, the team shows that blocking this “addiction” can greatly prevent cancer growth.


Full story »

All News summaries from Medicine & Health news
All News summaries for December 10, 2007

Expanded food and nutrition program shows $10 benefit for each $1 spent

31 minutes ago | User rating: not rated yet
A program to teach low-income adults about healthy food choices is a good bargain in terms of the health and economic benefits achieved, reports a cost-effectiveness study in the May/June issue of Journal of Nutrition ...

Novel mechanisms controlling insulin release and fat deposition discovered

34 minutes ago | User rating: not rated yet
Scientists at the Swedish medical university Karolinska Institutet have in two recent studies shown that a receptor called ALK7 plays important roles in the regulation of body fat deposition as well as the release of insulin ...

Too hot to handle! Scientists identify heat sensing regulator

45 minutes ago | User rating: not rated yet
Neuroscientists at Johns Hopkins are a step closer to understanding pain sensitivity - specifically why it’s variable instead of constant - having identified a gene that regulates a heat-activated molecular sensor. Their ...

Study: Most female child molesters were victims of sexual abuse

49 minutes ago | User rating: not rated yet
A University of Georgia study that is the first to systematically examine a large sample of female child molesters finds that many of them were themselves victims of sexual abuse as children.

Gene therapy slows progression of fatal neurodegenerative disease in children

49 minutes ago | User rating: not rated yet
Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper ...